

NOVAVAX INC
Form 8-K
August 26, 2008

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 26, 2008
NOVAVAX, INC.
(Exact name of Registrant as specified in its charter)**

**Delaware
(State or other jurisdiction of
incorporation or organization)**

**0-26770
(Commission File Number)**

**22-2816046
(I.R.S. Employer Identification
No.)**

**9920 Belward Campus Drive
Rockville, Maryland
(Address of principal executive offices)**

**20850
(Zip Code)**

**Registrant's telephone number, including area code: (240) 268-2000
(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant

under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**
-

Item 7.01 Regulation FD Disclosure.

On August 26, 2008, Novavax, Inc. (the Company) announced the results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate and will conduct a publicly available conference call to discuss those results.

On August 26, 2008, the Company also posted a presentation to its website reviewing the results of the clinical trial.

The Company expects to use the presentation during the conference call and at certain investor meetings.

The press release and presentation contain statements that are forward-looking statements subject to the cautionary statement about forward-looking statements set forth therein.

A copy of the press release is furnished as Exhibit 99.1 and a copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits

99.1 Press Release of Novavax, Inc., dated August 26, 2008

99.2 Presentation of Novavax, Inc., dated August 26, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novavax, Inc.
(Registrant)

August 26, 2008

By: /s/ Len Stigliano

Name:

Len Stigliano

Title: Chief Financial Officer, Vice President and
Treasurer